
Albert Català Temprano
Investigador
Research group
Professional network profiles
Last Publications
- Río P, Zubicaray J, Navarro S, Gálvez E, Sánchez-Domínguez R, Nicoletti E, Sebastián E, Rothe M, Pujol R, Bogliolo M, John-Neek P, Bastone AL, Schambach A, Wang W, Schmidt M, Larcher L, Segovia JC, Yáñez RM, Alberquilla O, Díez B, Fernández-García M, García-García L, Ramírez M, Galy A, Lefrere F, Cavazzana M, Leblanc T, García de Andoin N, López-Almaraz R, Català-Temprano A, Barquinero J, Rodríguez-Perales S, Rao G, Surrallés J, Soulier J, Díaz-de-Heredia C, Schwartz JD, Sevilla J and Bueren JA Haematopoietic gene therapy of non-conditioned patients with Fanconi anaemia-A: results from open-label phase 1/2 (FANCOLEN-1) and long-term clinical trials. Lancet . 404(10471): 2584-2592.
- Kotmayer L, Kozyra EJ, Kang G, Strahm B, Yoshimi A, Sahoo SS, Pastor VB, Attardi E, Voss R, Vinci L, Kaiser M, Dworzak MN, De Moerloose B, Sukova M, Starý J, Hasle H, Jahnukainen K, Polychronopoulou S, Kállay K, Smith OP, Malone A, Barzilai Birenboim S, Masetti R, Buechner J, Ussowicz M, Kjöllerström P, Bodova I, Kavcic M, Català-Temprano A, Turkiewicz D, Schmugge M, de Haas V, Okhomina VI, Sotomayor C, Catalán P, Wehr C, Salzer U, Germing U, Gattermann N, Bödör C, Gray N, Lewis S, Shimamura A, Giorgetti A, Erlacher M, Niemeyer CM and Wlodarski MW Age-dependent phenotypic and molecular evolution of pediatric MDS arising from GATA2 deficiency. BLOOD CANCER JOURNAL . 15(1): 121-121.
- Romero-Moya D, Pera J, Marin-Bejar O, Torralba-Sales E, Murillo-Sanjuán L, Diaz-de-Heredia C, Montoro J, Rodríguez-Ubreva J, Liquori A, Cervera J, Wlodarski MW, Català-Temprano A and Giorgetti A Multiple phenotypes and epigenetic profiles in a three-generation family history with GATA2 deficiency Leukemia . 39(4): 962-966.
Projects
- Project name:
- ADVANCED THERAPIES (RICORS-TERAV)
- Leader
- Susana Rives Solà
- Funding entities:
- Instituto de Salud Carlos III (ISCIII)
- Code
- RD24/0014/0006
- Starting - finishing date:
- 2025 - 2027
- Project name:
- Estudio multicéntrico fase 2 en pacientes pediátricos (0-18 años) con leucemia linfoblástica aguda B CD19+ en recaída o refractaria
- Leader
- Susana Rives Solà
- Funding entities:
- Instituto de Salud Carlos III (ISCIII)
- Code
- ICI21/00033
- Starting - finishing date:
- 2022 - 2025
- Project name:
- New approaches for the identification and functional characterization of prognostic genetic biomarkers in inherited childhood myelodysplastic/acute leukemia syndromes Acronym: GEMMA
- Leader
- Albert Català Temprano
- Funding entities:
- Fundació La Marató de TV3
- Code
- 202001-30
- Starting - finishing date:
- 2021 - 2024